Fortis Healthcare working capital

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

21.89×	21.89×	22.21×	25.96×	30.83×	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
36.55×	36.55×	33.12×	32.02×	31.70×
152.97×	152.97×	153.11×	162.59×	179.22×
−94.53×	−94.53×	−97.78×	−104.61×	−116.69×
−31.49×	−30.24×	13.97×	−7.05×	12.15×
0.62×	0.62×	0.58×	0.54×	0.52×
1.51×	1.51×	1.76×	1.70×	1.30×
0.77×	0.77×	0.90×	0.87×	0.75×

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

FORTIS₹754.90

Fortis Healthcare Ltd.

· Pharma & Health

₹ CrorePeersAPOLLOHOSP MAXHEALTH MEDANTA AUROPHARMA LUPIN ALKEM LAURUSLABS MANKINDMcap ₹56,992 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Inventory Days (DIO)	30.83	25.96	22.21	21.89	21.89
Receivable Days (DSO)	31.70	32.02	33.12	36.55	36.55
Payable Days (DPO)	179.22	162.59	153.11	152.97	152.97
Cash Conversion Cycle (days)	-116.69	-104.61	-97.78	-94.53	-94.53
Working Capital Turnover	12.15	-7.05	13.97	-30.24	-31.49
Asset Turnover	0.52	0.54	0.58	0.62	0.62
Cash Conversion (CFO/Net Income)	1.30	1.70	1.76	1.51	1.51
CFO/EBITDA	0.75	0.87	0.90	0.77	0.77

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.